Hutchmed's (HKG:0013) ORPATHYS will continue to be included in the updated National Reimbursement Drug List effective Jan. 1, 2025, on the same terms, a Thursday bourse filing said.
ORPATHYS is used for the treatment of certain patients with non-small cell lung cancer with MET exon 14 skipping alterations.
ORPATHYS was first included in the list on March 1, 2023.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.